Ironwood医药公司宣布,其产品Linzess(利那洛肽)因存在引发严重脱水的潜在风险,现明确禁用于两岁以下患者群体。这一更新基于对药物安全性的持续评估,旨在进一步保障儿童用药安全。
Ironwood医药公司宣布,其产品Linzess(利那洛肽)因存在引发严重脱水的潜在风险,现明确禁用于两岁以下患者群体。这一更新基于对药物安全性的持续评估,旨在进一步保障儿童用药安全。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.